Jacob Elguicze Purchases 20,000 Shares of Embecta (NASDAQ:EMBC) Stock

Embecta Corp. (NASDAQ:EMBC) CFO Jacob Elguicze purchased 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average price of $4.67 per share, with a total value of $93,400.00. Following the purchase, the chief financial officer directly owned 309,139 shares of the company’s stock, valued at approximately $1,443,679.13. The trade was a 6.92% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $5.10 on Friday. The firm has a market cap of $288.97 million, a price-to-earnings ratio of 3.45 and a beta of 0.81. The business has a 50-day simple moving average of $3.50 and a two-hundred day simple moving average of $6.41. Embecta Corp. has a fifty-two week low of $2.77 and a fifty-two week high of $15.55.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.29. The firm had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s quarterly revenue was down 8.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, research analysts predict that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be given a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 27th. Embecta’s dividend payout ratio (DPR) is presently 2.70%.

Analyst Upgrades and Downgrades

EMBC has been the topic of several recent research reports. BTIG Research cut shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Weiss Ratings downgraded shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Mizuho dropped their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, Bank of America cut their price objective on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $11.00.

Institutional Investors Weigh In On Embecta

A number of hedge funds have recently made changes to their positions in EMBC. Larson Financial Group LLC boosted its stake in Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the last quarter. One Wealth Advisors LLC bought a new stake in Embecta in the 2nd quarter worth approximately $33,000. Tower Research Capital LLC TRC increased its stake in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after acquiring an additional 6,224 shares during the last quarter. Wexford Capital LP purchased a new stake in shares of Embecta during the 3rd quarter worth approximately $94,000. Finally, Humankind Investments LLC purchased a new stake in shares of Embecta during the 2nd quarter worth approximately $111,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively purchased 70,000 shares worth approximately $334,200 on August 12. The insider buying could signal that management and the director believe Embecta’s shares are undervalued after their steep decline. SEC insider transaction filing
• Neutral Sentiment: Embecta also disclosed a quarterly dividend of $0.01 per share, or $0.04 annualized, with a yield of roughly 0.8%. The modest payout is unlikely to be a major near-term stock catalyst but may appeal to income-focused investors. Embecta dividend and insider trading report
• Neutral Sentiment: Multiple law firms, including Hagens Berman, Bronstein Gewirtz & Grossman, Kaplan Fox, Faruqi & Faruqi and Rosen, reminded investors that August 17 is the deadline to seek lead-plaintiff status. The notices target investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, and mostly repeat previously reported information. Hagens Berman class action deadline notice
• Negative Sentiment: The underlying securities class action alleges that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business and issued misleading fiscal 2026 guidance. If the claims gain traction, the company could face legal expenses, reputational damage and further questions about management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.